Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.
Heavily backed biotechs Denali Therapeutics and Odonate Therapeutics are looking to make hay while the sun shines by filing for two big IPOs.
Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.
Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.
Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.
Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit.
The heavily pretreated bladder cancer data suggest the cocktail can hold its own against a combination of rival drugs from Incyte and Merck.
Roivant’s Vivek Ramaswamy didn't sugarcoat its Alzheimer’s flop but said his company won't back away from the field.
The trials linked the drug to improvements on a depression scale, teeing Sage up to file for approval next year and sending its stock up 44%.
Just weeks after a phase 3 setback caused it to slash staff and R&D programs, Otonomy has bounced back with a positive late-stage trial.